Nimesulide inhibits IFN-γ-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms

Cancer Letters

Volumn 276, Issue 1, 2009, Pages 47-52

  Liang, Mei ^a   Yang, Hui ^a   Fu, Jian ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

B7 H1; Breast cancer; Interferon; Nimesulide; PD L1

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; LIGAND; NIMESULIDE; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; SULFONAMIDES;

EID: 60249094444     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.028     Document Type: Article

References (19)

1. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24 (2003) 96-102
2. Fodera D., D'Alessandro N., Cusimano A., Poma P., Notarbartolo M., Lampiasi N., Montalto G., and Cervello M. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann. NY Acad. Sci. 1028 (2004) 440-449
3. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., Sugiura T., Ogawa M., and Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6 (2000) 2006-2011
4. Fukutake M., Nakatsugi S., Isoi T., Takahashi M., Ohta T., Mamiya S., Taniguchi Y., Sato H., Fukuda K., Sugimura T., and Wakabayashi K. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 19 (1998) 1939-1942
5. Nam K.T., Hahm K.B., Oh S.Y., Yeo M., Han S.U., Ahn B., Kim Y.B., Kang J.S., Jang D.D., Yang K.H., and Kim D.Y. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin. Cancer Res. 10 (2004) 8105-8113
6. Shaik M.S., Chatterjee A., and Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma. Clin. Cancer Res. 10 (2004) 1521-1529
7. Deasy B.M., O'Sullivan-Coyne G., O'Donovan T.R., McKenna S.L., and O'Sullivan G.C. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms. Cancer Lett. 256 (2007) 246-258
8. Han S., and Roman J. COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer 51 (2006) 283-296
9. Blank C., Gajewski T.F., and Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54 (2005) 307-314
10. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., Elkum N., Alshabanah M., Bin Amer S., Tulbah A., Ajarim D., Al-Tweigeri T., and Dermime S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8 (2006) 190-198
11. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., Mizuno T., Yoriki R., Kashizuka H., Yane K., Tsushima F., Otsuki N., Yagita H., Azuma M., and Nakajima Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11 (2005) 2947-2953
12. Thompson R.H., Kuntz S.M., Leibovich B.C., Dong H., Lohse C.M., Webster W.S., Sengupta S., Frank I., Parker A.S., Zincke H., Blute M.L., Sebo T.J., Cheville J.C., and Kwon E.D. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66 (2006) 3381-3385
13. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X.G., and Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108 (2006) 19-24
14. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., Lennon V.A., Celis E., and Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002) 793-800
15. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., and Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99 (2002) 12293-12297
16. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D.B., Lau J.S., Zhu G., Tamada K., and Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65 (2005) 1089-1096
17. Zhang P., Su D.M., Liang M., and Fu J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol. Immunol. 45 (2008) 1470-1476
18. Wang M.T., Honn K.V., and Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 26 (2007) 525-534
19. Su B., Darby M.V., and Brueggemeier R.W. Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. J.Comb. Chem. 10 (2008) 475-483